Cofetuzumab pelidotin MedChemExpress (MCE)

Product Name	Cofetuzumab Pelidotin
Synonyms	Cofetuzumab Pelidotin
CAS	1869937-48-3
EINECS
Chemical Formula
Molecular Weight
inchi
Package	1 mg
Price	Email to quote
Descriptions	Cofetuzumab pelidotin Cofetuzumab pelidotin MedChemExpress (MCE) HY-P99829 1869937-48-3 PF-06647020 Descriptions Cofetuzumab pelidotin Cofetuzumab pelidotin MedChemExpress (MCE) HY-P99829 1869937-48-3 PF-06647020 ABBV-647 h6M24-vc0101 99.67% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101 HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research. Cofetuzumab pelidotin (PF-06647020) shows in vitro cytotoxic effects on PTK7 expressing cancer cell lines H446, H661 and OVCAR3 with EC50 values of 7.6, 27.5 and 105 ng/mL, respectively[1]. Cofetuzumab pelidotin (PF-06647020) (for 6 days) shows high potency and PTK7-specific cytotoxicity in a panel of cancer cell lines (A549, MDA-MB-468, KYSE-150, SKOV-3, PC9, NCI-H1975 cells) with IC50s of 0-1100 nM[2]. Cofetuzumab pelidotin is less stable with a much shorter T1/2 of less than 3 days[2]. Cofetuzumab pelidotin (PF-06647020 3 mg/kg Intraperitoneal injection twice a week for four cycles) induces striking in vivo anti-tumor effects on a subset of PDXs derived from NSCLC, OVCA and TNBC[1]. \| \| \| \| \| \| \| \| \| \| [1]. Marc Damelin, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017 Jan 11 9(372):eaag2611. [Content Brief] [2]. Chao Kong, et al. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Mol Cancer Ther. 2023 Oct 2 22(10):1128-1143. [Content Brief] [3]. Masaru Katoh. Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis. nn Transl Med. 2017 Dec 5(23):462. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-04-01 14:45:47

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-04-01 14:45:47

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-04-01 14:45:47

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-04-01 14:45:47

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-04-01 14:45:47

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-04-01 14:45:47

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-04-01 14:45:47

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact